Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05025397 · ClinicalTrials.gov registry record · Phase 1

A Study of Danavorexton in Anesthetized Adults

A Phase 1 study, sponsored by Takeda.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target

NCT05025397: Completed Phase 1 study, sponsored by Takeda.

NCT05025397 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05025397, a Phase 1 study, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target

Study Summary

The aims of the study are: * to assess the safety profile of danavorexton when it is administered with anesthetics. * to learn what effect danavorexton has on anesthetized adults. On Day 1, participants will receive a single intravenous (IV) infusion of danavorexton or a placebo after participants have been anesthetized for about 40 minutes. Clinic doctors will arrange a follow-up visit by phone or video on Day 7.

Interventions

  • DRUG Sevoflurane
  • DRUG Propofol
  • DRUG Danavorexton
  • DRUG Danavorexton Placebo

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2021-09-28
Est. Completion 2022-03-08
Phase Phase 1
Takeda

408 total trials

What the finished NCT05025397 record still lists

NCT05025397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).

The record links to 0 conditions, and to 4 interventions - of which Sevoflurane is the first listed.

NCT05025397 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05025397 about?

NCT05025397 is a clinical study titled "A Study of Danavorexton in Anesthetized Adults". The aims of the study are: * to assess the safety profile of danavorexton when it is administered with anesthetics. * to learn what effect danavorexton has on anesthetized adults. On Day 1, participants will receive a single intravenous (IV) infusion of danavorexton or a placebo after participants...

What is the current status of trial NCT05025397?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2021-09-28. Estimated completion is 2022-03-08.

What interventions are being tested in trial NCT05025397?

The interventions under investigation include: Sevoflurane (DRUG), Propofol (DRUG), Danavorexton (DRUG), Danavorexton Placebo (DRUG).

Who is sponsoring clinical trial NCT05025397?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05025397's enrollment target sits among peer trials

28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05025397, the US trial registry maintained by the National Library of Medicine. NCT05025397 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.